Abstract
This paper analyses (1) the impact of the inclusion of statins in the German reference pricing scheme in 2005 on the statin market, and (2) the effect of switching behaviour subsequent to the policy change on healthcare utilisation and costs. Patients with prescriptions for statins in 2004 were observed for 1 year before and 1 year after the policy change, which went into effect on 1 January 2005. Data on outpatient and inpatient visits, pharmaceutical consumption, and cost to the sickness fund were collected from a sickness fund with more than 5.8 million insured members in 2005. Compared to patients who were not affected by the policy change, patients treated previously with atorvastatin experienced higher non-adherence and increased discontinuation of treatment (P < 0.0001). Compared to patients who continued treatment with atorvastatin (non-switchers), patients who switched to another statin were hospitalised more often (P = 0.0439). However, difference-in-differences in hospitalisation due to coronary heart disease (P = 0.8751) and emergency visits (P = 0.5624) did not differ significantly between the two groups. Patients who switched more than once experienced a significant increase in hospital visits (P = 0.0061) and hospital visits due to cardiovascular disease (P = 0.0096) compared to non-switchers. Difference-in-differences in outpatient healthcare utilisation did not differ between non-switchers and switchers. Total savings resulting from the policy change ranged from € 94.4 million to € 108.7 million. Although manufacturers usually comply with reference pricing by reducing their retail prices to the reference price, regulators have to be aware of the consequences in cases where manufacturers react as in this situation.
Similar content being viewed by others
References
Puig-Junoy, J.: What is required to evaluate the impact of pharmaceutical reference pricing. Appl. Health Econ. Health Policy 4(2), 87–98 (2005). doi:10.2165/00148365-200504020-00003
Kaló, Z., Muszbek, N., Bodrogi, J., Bidló, J.: Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy 80(3), 402–412 (2007). doi:10.1016/j.healthpol.2006.04.002
McArthur, W.: Patient outcomes and public health consequences of reference pricing. In: López-Casasnovas, G., Jönsson, B. (eds.) Reference Pricing and Pharmaceutical Policy, pp. 145–160. Springer, Barcelona (2001)
Grootendorst, P., Stewart, D.: A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Health Econ. 15(7), 735–742 (2006). doi:10.1002/hec.1103
Schneeweiss, S., Soumerai, S., Maclure, M., Dormuth, C., Walker, A., Glynn, R.: Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin. Pharmacol. Ther. 74(4), 388–400 (2003). doi:10.1016/S0009-9236(03)00227-3
Schneeweiss, S., Walker, A., Glynn, R., Maclure, M., Dormuth, C., Soumerai, S.: Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 346(11), 822–829 (2002). doi:10.1056/NEJMsa003087
Grootendorst, P., Marshall, J., Holbrook, A., Dolovich, L., O’Brien, B., Levy, A.: The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Serv. Res. 40(5), 1297–1317 (2005). doi:10.1111/j.1475-6773.2005.00420.x
Stargardt, T., Schreyögg, J., Busse, R.: Arzneimittelfestbeträge: Gruppenbildung, Preisberechnung mittels Regressionsverfahren und Wirkungen. Gesundheitswesen 67(7), 468–477 (2005). doi:10.1055/s-2005-858485
Schneeweiss, S., Soumerai, S., Glynn, R., Maclure, M., Dormuth, C., Walker, A.: Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ 166(6), 737–745 (2002)
Federal Joint Committee. Explanatory statements on the grouping of statins. Germany, Federal Joint Committee (2004)
IQWIG: Nutzenbewertung der Statine unter besonderer Berücksichtigung von Atorvastatin. Institute for Quality and Efficiency in Health Care [IQWIG], Köln (2005)
Sikka, R., Xia, F., Aubert, R.: Estimating medication persistency using administrative claims data. Am. J. Manag. Care 11(7), 449–457 (2005)
Gibson, T., Mark, T., McGuigan, K.A., Axelsen, K., Wang, S.: The effects of prescription drug copayments on statin adherence. Am. J. Manag. Care 12(9), 509–517 (2006)
Avorn, J., Monette, J., Lacour, A., Bohn, R., Monane, M., Mogun, H., LeLorier, J.: Persistence of use of lipid-lowering medications. JAMA 279(18), 1458–1462 (1998). doi:10.1001/jama.279.18.1458
Schneeweiss, S., Patrick, A., Maclure, M., Dormuth, C., Glynn, R.: Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction. Circulation 115(16), 2128–2135 (2007). doi:10.1161/CIRCULATIONAHA.106.665992
Bertrand, M., Duflo, E., Mullainathan, S.: How much should we trust differences-in-differences estimates? Q. J. Econ. 119(1), 249–275 (2004). doi:10.1162/003355304772839588
Motheral, B., Fairman, K.: The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin. Ther. 19(2), 346–366 (1997). doi:10.1016/S0149-2918(97)80122-1
Schneeweiss, S., Maclure, M., Walker, A., Grootendorst, P., Soumerai, S.: On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker’s versus the clinician’s perspective. Health Policy 55(2), 97–109 (2001). doi:10.1016/S0168-8510(00)00120-2
Aldrich, J., Nelson, F.: Linear Probability, Logit, and Probit Models. SAGE, Beverly Hills (1984)
Liao, T.: Interpreting Probability Models, Logit, Probit and Other Generalized Linear Models. SAGE, Thousand Oaks, CA (1994)
Hoetker, G.: The use of logit and probit models in strategic management research: critical issues. Strateg. Manage. J. 28331–28343 (2007)
Busse, R., Riesberg, A.: Health Care System in Transition—Germany. European Observatory on Health Systems and Policies, Copenhagen (2004)
Nink, K., Schröder, H.: Ergänzende statistische Übersicht. In: Schwabe, U., Paffrath, D. (eds.) Arzneiverordnungsreport 2005, pp. 1053–1156. Springer, Heidelberg (2006)
Motheral, B., Fairman, K.: Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med. Care 39(12), 1293–1304 (2001). doi:10.1097/00005650-200112000-00005
Gibson, T., McLaughin, C., Smith, D.: A copayment increase for prescription drugs: the long-term and short-term effects on use and expenditures. Inquiry 42(3), 293–310 (2005)
Nair, K., Valuck, R., Allen, R., Lewis, S.: Impact of increased copayments on the discontinuation/switching rates of nonformulary medications. J. Pharm. Technol. 21(3), 137–143 (2005)
Danzon, P.M.: Reference pricing: theory and evidence. In: López-Casasnovas, G., Jönsson, B. (eds.) Reference Pricing and Pharmaceutical Policy, pp. 86–126. Barcelona: Springer, (2001)
Busse, R., Schreyögg, J., Henke, K.-D.: Pharmaceutical Regulation in Germany: improving efficiency and controlling expenditures. Int. J. Health Plann. Manage. 20(4), 329–349 (2005). doi:10.1002/hpm.818
Steiner, J., Prochazka, A.: The asessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. 50(1), 105–116 (1997). doi:10.1016/S0895-4356(96)00268-5
Nink, K., Schröder, H.: Ergänzende statistische Übersicht. In: Schwabe, U., Paffrath, D. (eds.) Arzneiverordnungsreport 2006, pp. 981–1082. Springer, Heidelberg (2007)
Acknowledgments
The author would like to thank the Techniker Krankenkasse for granting access to the sickness fund databases. In particular, the author is very grateful to Dr. Frank Verheyen and Anke Höhn for their helpful comments and their assistance with data extraction.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stargardt, T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur J Health Econ 11, 267–277 (2010). https://doi.org/10.1007/s10198-009-0172-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-009-0172-3